Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 33 of 33 publications.

Poulos C, Marcek T, Chintakayala P, Boeri M, Francis A, Langevin E, Petigara T, O'Connor J, Samant S. Preferences of nurses in the United Kingdom for attributes of pediatric hexavalent vaccines: a discrete-choice experiment. Expert Rev Pharmacoecon Outcomes Res. 2025 Apr;25(4):543-50. doi: 10.1080/14737167.2025.2450352

Horn EK, La EM, Bektas M, Khan S, Gerber SI. Disparities in respiratory syncytial virus risk factors, diagnosis, and outcomes in adults by race, ethnicity, and other social determinants of health in the United States. Expert Rev Pharmacoecon Outcomes Res. 2025 Apr;25(4):459-71. doi: 10.1080/14737167.2024.2441867

Moss E, Burrell A, Lee J, Reichenbach D, Mitchell S, Yan S, Thiruvillakkat K. Economic and humanistic burden in kidney transplant rejection: a literature review. Expert Rev Pharmacoecon Outcomes Res. 2024 Mar;24(3):343-52. doi: 10.1080/14737167.2024.2305140

Fernandez MM, Bell T, Tumminello B, Khan S, Zhou S, Oton AB. Disease and economic burden of surgery in desmoid tumors: a review. Expert Rev Pharmacoecon Outcomes Res. 2023 Jul;23(6):607-18. doi: 10.1080/14737167.2023.2203915

Kandzari DE, Weber MA, Poulos C, Coulter J, Cohen SA, DeBruin V, Jones D, Pathak A. Patient preferences for pharmaceutical and device-based treatments for uncontrolled hypertension: discrete choice experiment. Circ Cardiovasc Qual Outcomes. 2023 Jan;16(1):e008997. doi: 10.1161/CIRCOUTCOMES.122.008997

Poulos C, Xu Y, Botha W, Leach C, Wrobleski KK, Gordon K, Missmer SA, Estes SJ. A discrete-choice experiment study of physicians' prioritization of attributes of medical treatments for endometriosis-associated pain. Expert Rev Pharmacoecon Outcomes Res. 2023 Jan;23(1):111-21. doi: 10.1080/14737167.2023.2152006

Herring W, Ciarametaro M, Mauskopf J, Wamble D, Sils B, Dubois R. What might have happened: the impact of interrupting entry of innovative drugs on disease outcomes in the United States. Expert Rev Pharmacoecon Outcomes Res. 2022 Jun;22(4):529-41. doi: 10.1080/14737167.2022.2035219

Flem E, Graham J, Yi Z, Wisloff T, Johnson KD. Cost and health impact analysis of herpes zoster vaccination in Norway. Expert Rev Pharmacoecon Outcomes Res. 2022 Mar;22(2):315-26. doi: 10.1080/14737167.2021.1973893

Goyal RK, Cuyun Carter G, Nagar SP, Nash Smyth E, Price GL, Parikh RC, Huang YJ, Li L, Davis KL, Kaye JA. Treatment patterns, adverse events, and direct and indirect economic burden in a privately insured population of patients with HR+/HER2- metastatic breast cancer in the United States. Expert Rev Pharmacoecon Outcomes Res. 2021;21(4):699-710. doi: 10.1080/14737167.2020.1804871

Poulos C, Soliman AM, Tekin S, Agarwal SK. Patient preferences for elagolix and leuprolide for treating endometriosis-related pain in the United States. Expert Rev Pharmacoecon Outcomes Res. 2020 Nov 3;1-9. doi: 10.1080/14737167.2021.1832468

Himmler S, Mueller M, Sherif B, Ostwald D. A case study applying a novel approach to estimate the social impact of a medical innovation - the use of secukinumab for psoriatic arthritis in Germany. Expert Rev Pharmacoecon Outcomes Res. 2019 Jul 29. doi: 10.1080/14737167.2019.1644169

Kapral MK, Austin PC, Jeyakumar G, Hall R, Chu A, Khan AM, Jin AY, Martin C, Manuel D, Silver FL, Swartz RH, Tu JV. Rural-urban differences in stroke risk factors, incidence, and mortality in people with and without prior stroke. Circ Cardiovasc Qual Outcomes. 2019 Feb;12(2):e004973. doi: 10.1161/CIRCOUTCOMES.118.004973

Jarmul J, Pletcher MJ, Hassmiller Lich K, Wheeler SB, Weinberger M, Avery CL, Jonas DE, Earnshaw S, Pignone M. Cardiovascular genetic risk testing for targeting statin therapy in the primary prevention of atherosclerotic cardiovascular disease: a cost-effectiveness analysis. Circ Cardiovasc Qual Outcomes. 2018 Apr;11(4):e004171. doi: 10.1161/CIRCOUTCOMES.117.004171

Barrett A, DiBenedetti DB, Rane P, Wade S, Qian Y. Assessing attitudes and treatment preferences among patients with hyperlipidemia: patient focus groups. Poster presented at the AHA QCOR 2017 Scientific Sessions; April 2, 2017. Arlington, VA. [abstract] Circ Cardiovasc Qual Outcomes. 2017 Mar; 10(Suppl 3):A022.

Clark M, DiBenedetti D, Perez V. Cognitive dysfunction and work productivity in major depressive disorder. Expert Rev Pharmacoecon Outcomes Res. 2016 Jun 8. doi: 10.1080/14737167.2016.1195688

Jalbert JJ, Nguyen LL, Gerhard-Herman MD, Kumamaru H, Chen CY, Williams LA, Liu J, Rothman AT, Jaff MR, Seeger JD, Benenati JF, Schneider PA, Aronow HD, Johnston JA, Brott TG, Tsai TT, White CJ, Setoguchi S. Comparative effectiveness of carotid artery stenting versus carotid endarterectomy among Medicare beneficiaries. Circ Cardiovasc Qual Outcomes. 2016 May;9(3):275-85. doi: 10.1161/CIRCOUTCOMES.115.002336

Brennan VK, Mauskopf JA, Colosia AD, Copley-Merriman K, Hass B, Palencia R. Utility estimates for patients with type 2 diabetes mellitus after experiencing a myocardial infarction or stroke: a systematic review. Expert Rev Pharmacoecon Outcomes Res. 2015 Feb;15(1):111-23.

Chen WH, McLeod L, Nelson LM, Williams VS, Fehnel SE. Quantitative challenges facing patient-centered outcomes research. Expert Rev Pharmacoecon Outcomes Res. 2014 Jun 14;14(3):379-86.

Von Schéele B, Mauskopf J, Brodtkorb TH, Ainsworth C, Berardo CG, Patel A. Relationship between modeling technique and reported outcomes: case studies in models for the treatment of schizophrenia. Expert Rev Pharmacoecon Outcomes Res. 2014 Apr;14(2):235-57. doi: 10.1586/14737167.2014.891443

Pletcher MJ, Pignone M, Earnshaw SR, McDade CL, Phillips KA, Auer R, Zablotska L, Greenland P. Using the coronary artery calcium score to guide statin therapy: a cost-effectiveness analysis. Circ Cardiovasc Qual Outcomes. 2014 Mar 1;7(2):276-84. doi: 10.1161/CIRCOUTCOMES.113.000799

Davis AE, Mehrotra S, Friedewald J, Ladner D. Characteristics of a simulation model of the national kidney transplantation system. Poster presented at the 2013 Winter Simulation Conference: Simulation: Making Decisions in a Complex World; December 2013. [abstract] Ieee/Acm Trans Comput Biol Bioinform. 2013 Dec; p.2320-9.

Brookhart MA, Wyss MS, Layton JB, Sturmer T. Propensity score methods for confounding control in non-experimental research. Circ Cardiovasc Qual Outcomes. 2013 Sep 1;6(5):604-11. doi: 10.1161/CIRCOUTCOMES.113.000359

Walker DR, Ivanova J, Betts KA, Rao S, Wu EQ. Association of patient characteristics with the initiation of dabigatran versus warfarin among anticoagulant naive patients with non-valvular atrial fibrillation. Poster presented at the QCAR 2013 Annual Meeting; May 15, 2013. Baltimore, MD. [abstract] Circ Cardiovasc Qual Outcomes. 2013 May; 6(Suppl_1):A211. doi: 10.1161/circoutcomes.6.suppl_1.A211

Fehnel S, DeMuro C, McLeod L, Coon C, Gnanasakthy A. FDA patient-reported outcome guidance: great expectations and unintended consequences. Expert Rev Pharmacoecon Outcomes Res. 2013;13(4):441-6.

Huybrechts KF, Seeger JD, Rothman KJ, Glynn RJ, Avorn J, Schneeweiss S. Bias in comparative effectiveness studies due to regional variation in medical practice intensity: a legitimate concern, or much ado about nothing? Circ Cardiovasc Qual Outcomes. 2012 Sep 1;5(5):e61-4.

Mauskopf J, Talbird S, Standaert B. Categorization of methods used in cost-effectiveness analyses of vaccination programs based on outcomes from dynamic transmission models. Expert Rev Pharmacoecon Outcomes Res. 2012 Jun 1;12(3):357-71.

DeMuro CJ, Lewis SA, DiBenedetti DB, Price MA, Fehnel SE. Successful implementation of cognitive interviews in special populations. Expert Rev Pharmacoecon Outcomes Res. 2012 Apr 1;12(2):181-7.

McLeod LD, Coon CD, Martin SA, Fehnel SE, Hays RD. Interpreting patient-reported outcome results: uS FDA guidance and emerging methods. Expert Rev Pharmacoecon Outcomes Res. 2011 Apr 1;11(2):163-9.

Wolowacz SE. Pharmacoeconomics of dabigatran etexilate for prevention of thromboembolism after joint replacement surgery. Expert Rev Pharmacoecon Outcomes Res. 2011 Feb 1;11(1):9-25.

Ferreira-Gonzalez I, Marsal JR, Mitjavila F, Parada A, Ribera A, Cascant P, Soriano N, Sanchez PL, Aros F, Heras M, Bueno H, Marrugat J, Cunat J, Civeira E, Permanyer-Miralda G. Patient registries of acute coronary syndrome: assessing or biasing the clinical real world data? Circ Cardiovasc Qual Outcomes. 2009 Nov;2(6):540-7. doi: 10.1161/CIRCOUTCOMES.108.844399

Mauskopf JA, Earnshaw SR, Mullins C. Budget impact analysis: review of the state of the art. Expert Rev Pharmacoecon Outcomes Res. 2005 Feb;5(1):65-79.

Ryan M, Watson V, Amaya-Amaya M. Methodological issues in the monetary valuation of benefits in healthcare. Expert Rev Pharmacoecon Outcomes Res. 2003 Dec;3(6):717-27. doi: 10.1586/14737167.3.6.717

Duff SB, Mordin MM. Strategies for assessing health economic and quality-of-life outcomes in multiple sclerosis. Expert Rev Pharmacoecon Outcomes Res. 2002 Dec;2(6):577-87.